Sivan Goren
CEO
Claimed by owner 
Serojec
Former names:
Drugs for Treating Premature Ejaculation
Serojec
About
Serojec develops drugs to treat premature ejaculation, by combining various drugs on the market. One drug is from the tricyclic family of antidepressants, used in low dosage, which then reaches only the spinal column, not the brain. The second drug is an alkaloid that relaxes the blood vessels. The combination enables each drug to neutralize the other's side effects. The alkaloid is a known drug for the treatment of premature ejaculation. The combinations of both drugs are patented.
The company has completed a Phase I trial to verify that the project is safe. A secondary purpose was to show signs of effectiveness. The trial showed that the duration of erection was extended several times over, even though all of the volunteers in the trial were functioning normally. The trial was conducted in cooperation with the University of Vienna.
The company has completed a Phase I trial to verify that the project is safe. A secondary purpose was to show signs of effectiveness. The trial showed that the duration of erection was extended several times over, even though all of the volunteers in the trial were functioning normally. The trial was conducted in cooperation with the University of Vienna.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
-
Geographic markets
-
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
0
Investors
0
The Team
(2)
SG
DDD
Dr. Daniel Drai
Founder
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Media gallery
(0)Locations
Israel
Tel Aviv, Israel
Locations
Israel
Tel Aviv, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,